Stanley H. Appel, MD
Articles
The Complexity of Frontotemporal Dementia and Potential of COYA 301: Stanley H. Appel, MD
January 5th 2024The director of the Ann Kimball and John W. Johnson Center for Cellular Therapeutics at Houston Methodist Hospital discussed the clinical manifestations of frontotemporal dementia (FTD) and how Coya Therapeutics is moving toward precision medicine with their FTD candidate, COYA 301. [WATCH TIME: 4 minutes]
Tackling Inflammation With Innovative Alzheimer Disease Treatments: Stanley H. Appel, MD
December 7th 2023The director of the Ann Kimball and John W. Johnson Center for Cellular Therapeutics at Houston Methodist Hospital talked about the phase 2 study assessing low-dose COYA 301 in mild-to-moderate Alzheimer disease and the focus on inflammation in this patient population. [WATCH TIME: 5 minutes]
Focus on Gene Therapy and Neuroinflammation in ALS Research: Stanley H. Appel, MD
April 3rd 2023The director of the Ann Kimball and John W. Johnson Center for Cellular Therapeutics at Houston Methodist Hospital spoke on about advances in ALS research and promising therapies on the horizon at the 2023 MDA conference. [WATCH TIME: 8 minutes]
Understanding Drug Interactions, Treg Dysfunction in ALS: Stanley Appel, MD
March 2nd 2023The director of the Ann Kimball & John W. Johnson Center for Cellular Therapeutics at Houston Methodist provided insight on previously approved therapies for ALS, and whether they can work synergistically with agents that enhance regulatory T cells function. [WATCH TIME: 5 minutes]
